CHMP give positive opinion for Atectura Breezhaler and Bemrist Breezhaler
Both of these products are indacaterol/mometasone furoate combination formulations. They were recommended for market authorisation for use in asthma. The full recommendation document will be published by the EMA later.
Source:
European Medicines Agency